Achieve Life Sciences' Cytisinicline to Unlock $760 Million Market Opportunity in Smoking Cessation, Morgan Stanley Says

MT Newswires Live

08/13

Achieve Life Sciences' (ACHV) Cytisinicline treatment for smoking cessation in adults will unlock about a $760 million market opportunity for the company, Morgan Stanley said in a Thursday note.

The company plans to resubmit the new drug application for Cytisinicline in Q4, with potential approval from the US Food and Drug Administration in H1 2027, the brokerage noted.

Achieve Life Sciences has developed an improved formulation and simpler treatment schedule for the drug, with its phase 3 study demonstrating "significantly greater" smoking abstinence rates compared with placebo, Morgan Stanley said

The company is also evaluating Cytisinicline in e-cigarette cessation, potentially unlocking an additional $330 million market opportunity, the investment firm added.

Morgan Stanley initiated coverage on Achieve Life Sciences with an overweight rating and a $13 price target.

Price: 7.08, Change: +0.39, Percent Change: +5.81

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2659657761"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2659657761\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2659657761?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 23:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659657761","market":"hk","top_or_hot":-1,"title":"Achieve Life Sciences' Cytisinicline to Unlock $760 Million Market Opportunity in Smoking Cessation, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ACHV\">Achieve Life</a> Sciences' (ACHV) Cytisinicline treatment for smoking cessation in adults will unlock about a $760 million market opportunity for the company, Morgan Stanley said in a Thursday note.</p><p>The company plans to resubmit the new drug application for Cytisinicline in Q4, with potential approval from the US Food and Drug Administration in H1 2027, the brokerage noted.</p><p>Achieve Life Sciences has developed an improved formulation and simpler treatment schedule for the drug, with its phase 3 study demonstrating \"significantly greater\" smoking abstinence rates compared with placebo, Morgan Stanley said</p><p>The company is also evaluating Cytisinicline in e-cigarette cessation, potentially unlocking an additional $330 million market opportunity, the investment firm added.</p><p>Morgan Stanley initiated coverage on Achieve Life Sciences with an overweight rating and a $13 price target.</p><p>Price: 7.08, Change: +0.39, Percent Change: +5.81</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Achieve Life Sciences' Cytisinicline to Unlock $760 Million Market Opportunity in Smoking Cessation, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAchieve Life Sciences' Cytisinicline to Unlock $760 Million Market Opportunity in Smoking Cessation, Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-13 23:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ACHV\">Achieve Life</a> Sciences' (ACHV) Cytisinicline treatment for smoking cessation in adults will unlock about a $760 million market opportunity for the company, Morgan Stanley said in a Thursday note.</p><p>The company plans to resubmit the new drug application for Cytisinicline in Q4, with potential approval from the US Food and Drug Administration in H1 2027, the brokerage noted.</p><p>Achieve Life Sciences has developed an improved formulation and simpler treatment schedule for the drug, with its phase 3 study demonstrating \"significantly greater\" smoking abstinence rates compared with placebo, Morgan Stanley said</p><p>The company is also evaluating Cytisinicline in e-cigarette cessation, potentially unlocking an additional $330 million market opportunity, the investment firm added.</p><p>Morgan Stanley initiated coverage on Achieve Life Sciences with an overweight rating and a $13 price target.</p><p>Price: 7.08, Change: +0.39, Percent Change: +5.81</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACHV","symbol_name":"Achieve Life Sciences, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2659657761","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2659657761","pubTimestamp":1786635970,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Achieve Life Sciences'  Cytisinicline treatment for smoking cessation in adults will unlock about a $760 million market opportunity for the company, Morgan Stanley said in a Thursday note.The company plans to resubmit the new drug application for Cytisinicline in Q4, with potential approval from the US Food and Drug Administration in H1 2027, the brokerage noted.Achieve Life Sciences has developed an improved formulation and simpler treatment schedule for the drug, with its phase 3 study demonstrating \"significantly greater\" smoking abstinence rates compared with placebo, Morgan Stanley saidThe company is also evaluating Cytisinicline in e-cigarette cessation, potentially unlocking an additional $330 million market opportunity, the investment firm added.Morgan Stanley initiated coverage on Achieve Life Sciences with an overweight rating and a $13 price target.Price: 7.08, Change: +0.39, Percent Change: +5.81","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACHV":"Achieve Life Sciences, Inc.","BK4139":"生物科技"},"translate_title":"摩根士丹利表示，实现 Life Sciences 的 Cytisinicline 将释放 7.6 亿美元的戒烟市场机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACHV":1},"content_text":"Achieve Life Sciences' (ACHV) Cytisinicline treatment for smoking cessation in adults will unlock about a $760 million market opportunity for the company, Morgan Stanley said in a Thursday note.The company plans to resubmit the new drug application for Cytisinicline in Q4, with potential approval from the US Food and Drug Administration in H1 2027, the brokerage noted.Achieve Life Sciences has developed an improved formulation and simpler treatment schedule for the drug, with its phase 3 study demonstrating \"significantly greater\" smoking abstinence rates compared with placebo, Morgan Stanley saidThe company is also evaluating Cytisinicline in e-cigarette cessation, potentially unlocking an additional $330 million market opportunity, the investment firm added.Morgan Stanley initiated coverage on Achieve Life Sciences with an overweight rating and a $13 price target.Price: 7.08, Change: +0.39, Percent Change: +5.81","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}